{
  "context": {
    "rules": [
      "Rule1: Provided that a regulatory body approves an organization's application, it is not the case that the regulatory body denies the organization's application.",
      "Rule2: Either an organization uses a vehicle or the organization employs alternative transportation.",
      "Rule3: Should an organization adopt alternative transportation, then the treatment is approved for the market.",
      "Rule4: In the event that an organization violates a protocol, the organization faces penalties.",
      "Rule5: An organization violates a protocol or, if it is not the case that using a vehicle implies market approval for the treatment, then the organization delays the study.",
      "Rule6: Whenever an organization hires a consultant, the organization appeals a decision.",
      "Rule7: If an organization performs an internal review, then should the organization violate a protocol, it will not face penalties.",
      "Rule8: Either an organization makes a public disclosure, or the organization hires a consultant, or the organization conducts an internal review.",
      "Rule9: Provided that an organization receives clearance for a treatment, the treatment receives market approval.",
      "Rule10: Should an organization achieve phase 1 success for a treatment, then the organization receives clearance for that treatment.",
      "Rule11: In the event that an organization achieves phase 2 success for a treatment, the organization receives clearance for the treatment.",
      "Rule12: If a study is accepted for publication, then under the condition that the organization completes an animal study, the treatment receives market approval.",
      "Rule13: Should an organization submit a study to a journal, then if the study undergoes peer review, the study is accepted for publication.",
      "Rule14: In the event that an organization performs data analysis on a study, the organization submits the study to a journal.",
      "Rule15: If an organization engages in international collaboration, then provided that the organization completes an animal study, the treatment receives market approval.",
      "Rule16: An organization pursues international collaboration or the organization enters a domestic partnership.",
      "Rule17: Under the condition that an organization enters a partnership agreement with a partner, then if the organization has a domestic partnership, then if the organization completes an animal study, the treatment receives market approval.",
      "Rule18: Provided that an organization attends a meeting with a regulatory body, then if the organization schedules a meeting, a regulatory meeting happens.",
      "Rule19: Should an organization fail to obtain funding for a disease, then it is not the case that the organization receives funding for the disease.",
      "Rule20: Whenever an organization submits data to a regulatory body, the regulatory body passes the organization's review.",
      "Rule21: If it is not true that using a vehicle implies market approval for the treatment, then the organization does not delay the study.",
      "Rule22: In the event that it is not the case that conducting research on a disease leads to developing a treatment, then the organization applies for authorization.",
      "Rule23: If it is not the case that initiating a trial results in phase 1 or phase 2 success, then the organization abandons the trial for the treatment.",
      "Rule24: If it is not the case that submitting data results in an animal study completion implying market approval, then the organization schedules a meeting with the regulatory body.",
      "Rule25: In the event that it is not true that submitting data implies that an animal study completion leads to market approval, then a regulatory meeting does not take place.",
      "Rule26: If it is not the case that the negation of passing review implying animal study completion leads to market approval results in a request for additional data, then the regulatory body denies the organization's application.",
      "Rule27: Under the condition that it is not true that not conducting research leading to treatment development implies not applying for authorization, then the organization receives funding for the disease.",
      "Rule28: In the event that it is not the case that not not conducting research implying treatment development leading to not applying for authorization results in failing funding, then the organization restructures.",
      "Rule29: Provided that it is not true that not not conducting research resulting in treatment development implying not applying for authorization leads to failing funding, then the organization does not restructure.",
      "Rule30: Should it not be the case that not market approval implies having authorization, then the organization conducts research on the disease.",
      "Rule31: If an organization does not attend a meeting with a regulatory body, then the organization misses the meeting.",
      "Rule32: Provided that a treatment does not obtain market approval, it is not the case that the organization has authorization."
    ],
    "facts": [
      "Fact1: A regulatory body approves an organization's application.",
      "Fact2: An organization initiates a clinical trial for a treatment.",
      "Fact3: An organization's study undergoes peer review.",
      "Fact4: An organization performs data analysis on a study.",
      "Fact5: An organization enters a partnership agreement with a partner.",
      "Fact6: An organization completes a study involving animal subjects.",
      "Fact7: An organization submits data to a regulatory body.",
      "Fact8: It is not the case that a regulatory body requests additional data from an organization.",
      "Fact9: An organization does not appeal a decision.",
      "Fact10: An organization does not make a public disclosure.",
      "Fact11: An organization does not abandon a clinical trial for a treatment.",
      "Fact12: An organization does not develop a treatment for a disease.",
      "Fact13: An organization does not miss a meeting with a regulatory body."
    ]
  },
  "question": "A treatment receives market approval."
}